Pharmaceuticals, Biotechnology and Life Sciences
London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
On Thursday, STADA Arzneimittel AG confirmed that it has received another legally non-binding conditional expression of interest regarding a bid for the acquisition of up to 100 percent of the shares in the company at an indicative takeover price of €58.00 per share.
Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.
e-Therapeutics’s Executive Director & Company Secretary Sean Nicolson is leaving the company in order to focus on other business commitments.
Active Biotech has reported net loss of € 1,6 million for Q4, which is decrease of loss comparing to the same period 2015 when the net loss was € 4,3 million.
Weifa ASA, Norwegian health company has reported net income of € 0,9 million for Q4 2016 which is increase comparing to the same period last year when the comapany had € 0,3 million loss. The company has more than tripled its net income for year 2016. It has reported € 2,03 million for whole 2016 and net income for the 2015 was € 0,65 million.
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.